C
Sarepta Therapeutics, Inc.
SRPT
$105.56
-$2.11-1.96%
C
Hold
11/7/2024Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to C- from D on 11/7/2024 due to a significant increase in the growth index, efficiency index and valuation index. EBIT increased 3,266.33% from -$701 to $22.2M, net income increased 420.29% from $6.46M to $33.61M, and earnings per share increased from $0.0683 to $0.3387.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to C- from D on 11/7/2024 due to a significant increase in the growth index, efficiency index and valuation index. EBIT increased 3,266.33% from -$701 to $22.2M, net income increased 420.29% from $6.46M to $33.61M, and earnings per share increased from $0.0683 to $0.3387.
D
Sell
10/14/2024Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D from D+ on 10/14/2024 due to a large decline in the total return index.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D from D+ on 10/14/2024 due to a large decline in the total return index.
D
Sell
9/25/2024Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D+ from D on 9/25/2024 due to a large increase in the total return index.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D+ from D on 9/25/2024 due to a large increase in the total return index.
D
Sell
9/10/2024Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D from D+ on 9/10/2024 due to a substantial decline in the total return index.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D from D+ on 9/10/2024 due to a substantial decline in the total return index.
D
Sell
8/8/2024Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D+ from C- on 8/8/2024 due to a substantial decline in the growth index and solvency index. EBIT declined 102.01% from $34.91M to -$701, earnings per share declined from $0.3687 to $0.0683, and total revenue declined 12.22% from $413.46M to $362.93M.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D+ from C- on 8/8/2024 due to a substantial decline in the growth index and solvency index. EBIT declined 102.01% from $34.91M to -$701, earnings per share declined from $0.3687 to $0.0683, and total revenue declined 12.22% from $413.46M to $362.93M.
C
Hold
7/1/2024Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to C- from D+ on 7/1/2024 due to an increase in the total return index and volatility index.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to C- from D+ on 7/1/2024 due to an increase in the total return index and volatility index.
D
Sell
5/3/2024Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D+ from D- on 5/3/2024 due to a substantial increase in the growth index, efficiency index and volatility index. EBIT increased 41.75% from $24.63M to $34.91M, total capital increased 4.46% from $2.26B to $2.36B, and total revenue increased 4.2% from $396.78M to $413.46M.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D+ from D- on 5/3/2024 due to a substantial increase in the growth index, efficiency index and volatility index. EBIT increased 41.75% from $24.63M to $34.91M, total capital increased 4.46% from $2.26B to $2.36B, and total revenue increased 4.2% from $396.78M to $413.46M.
D
Sell
11/6/2023Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D- from E+ on 11/6/2023 due to an increase in the volatility index, growth index and solvency index. EBIT increased 84.39% from -$133.52M to -$20.84M, total revenue increased 27.02% from $261.24M to $331.82M, and the quick ratio increased from 4.27 to 4.63.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D- from E+ on 11/6/2023 due to an increase in the volatility index, growth index and solvency index. EBIT increased 84.39% from -$133.52M to -$20.84M, total revenue increased 27.02% from $261.24M to $331.82M, and the quick ratio increased from 4.27 to 4.63.
E
Sell
10/31/2023Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to E+ from D- on 10/31/2023 due to a decline in the volatility index and total return index.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to E+ from D- on 10/31/2023 due to a decline in the volatility index and total return index.
D
Sell
9/19/2023Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D- from E+ on 9/19/2023 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$5.86 to -$0.27, operating cash flow increased 41.63% from -$209.4M to -$122.23M, and the quick ratio increased from 4.04 to 4.27.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D- from E+ on 9/19/2023 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$5.86 to -$0.27, operating cash flow increased 41.63% from -$209.4M to -$122.23M, and the quick ratio increased from 4.04 to 4.27.
E
Sell
6/26/2023Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to E+ from D- on 6/26/2023 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from -$1.2437 to -$5.86, operating cash flow declined 126.64% from -$92.39M to -$209.4M, and EBIT declined 36.95% from -$100.83M to -$138.09M.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to E+ from D- on 6/26/2023 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from -$1.2437 to -$5.86, operating cash flow declined 126.64% from -$92.39M to -$209.4M, and EBIT declined 36.95% from -$100.83M to -$138.09M.
D
Sell
3/14/2023Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index and valuation index. Debt to equity increased from 3.64 to 4.05, and the quick ratio declined from 3.81 to 3.63.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index and valuation index. Debt to equity increased from 3.64 to 4.05, and the quick ratio declined from 3.81 to 3.63.
D
Sell
2/23/2023Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D- from D on 2/8/2023 due to a significant decline in the growth index, solvency index and valuation index. Debt to equity increased from 1.54 to 3.64, earnings per share declined from -$2.65 to -$2.9413, and the quick ratio declined from 3.96 to 3.81.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D- from D on 2/8/2023 due to a significant decline in the growth index, solvency index and valuation index. Debt to equity increased from 1.54 to 3.64, earnings per share declined from -$2.65 to -$2.9413, and the quick ratio declined from 3.96 to 3.81.
D
Sell
5/16/2022Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index and volatility index.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index and volatility index.
E
Sell
5/13/2022Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/5/2022Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D from E+ on 5/5/2022 due to a significant increase in the growth index and total return index. EBIT increased 17.5% from -$105.31M to -$86.88M, earnings per share increased from -$1.4198 to -$1.2037, and total revenue increased 4.65% from $201.46M to $210.83M.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D from E+ on 5/5/2022 due to a significant increase in the growth index and total return index. EBIT increased 17.5% from -$105.31M to -$86.88M, earnings per share increased from -$1.4198 to -$1.2037, and total revenue increased 4.65% from $201.46M to $210.83M.
E
Sell
4/20/2022Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index.
D
Sell
4/18/2022Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D- from D on 4/18/2022 due to a significant decline in the growth index and total return index. EBIT declined 205.63% from -$34.46M to -$105.31M, and earnings per share declined from -$0.6027 to -$1.4198.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D- from D on 4/18/2022 due to a significant decline in the growth index and total return index. EBIT declined 205.63% from -$34.46M to -$105.31M, and earnings per share declined from -$0.6027 to -$1.4198.
D
Sell
11/9/2021Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
E
Sell
11/8/2021Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to E+ from D on 11/8/2021 due to a significant decline in the total return index, solvency index and volatility index. Debt to equity increased from 2.29 to 2.33.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to E+ from D on 11/8/2021 due to a significant decline in the total return index, solvency index and volatility index. Debt to equity increased from 2.29 to 2.33.
D
Sell
8/8/2019Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D from D+ on 8/8/2019 due to a decline in the efficiency index, solvency index and growth index. Net income declined 260.64% from -$76.64M to -$276.4M, earnings per share declined from -$1.07 to -$3.74, and EBIT declined 33.7% from -$76.39M to -$102.13M.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D from D+ on 8/8/2019 due to a decline in the efficiency index, solvency index and growth index. Net income declined 260.64% from -$76.64M to -$276.4M, earnings per share declined from -$1.07 to -$3.74, and EBIT declined 33.7% from -$76.39M to -$102.13M.
D
Sell
7/16/2019Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D+ from D on 7/16/2019 due to an increase in the solvency index, efficiency index and total return index. The quick ratio increased from 7.13 to 10.57, net income increased 45.6% from -$140.9M to -$76.64M, and total capital increased 26.18% from $1.45B to $1.83B.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D+ from D on 7/16/2019 due to an increase in the solvency index, efficiency index and total return index. The quick ratio increased from 7.13 to 10.57, net income increased 45.6% from -$140.9M to -$76.64M, and total capital increased 26.18% from $1.45B to $1.83B.
D
Sell
12/18/2018Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D from D+ on 12/18/2018 due to a large decline in the total return index and volatility index.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D from D+ on 12/18/2018 due to a large decline in the total return index and volatility index.
D
Sell
11/6/2018Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D+ from D on 11/6/2018 due to an increase in the efficiency index, volatility index and total return index. Net income increased 30.09% from -$109.27M to -$76.39M.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D+ from D on 11/6/2018 due to an increase in the efficiency index, volatility index and total return index. Net income increased 30.09% from -$109.27M to -$76.39M.
D
Sell
11/3/2017Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D from D- on 11/3/2017 due to a noticeable increase in the growth index, solvency index and efficiency index. The quick ratio increased from 4.83 to 9.12, total capital increased 87.26% from $388.99M to $728.44M, and EBIT increased 63.04% from -$54.58M to -$20.17M.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D from D- on 11/3/2017 due to a noticeable increase in the growth index, solvency index and efficiency index. The quick ratio increased from 4.83 to 9.12, total capital increased 87.26% from $388.99M to $728.44M, and EBIT increased 63.04% from -$54.58M to -$20.17M.
D
Sell
8/7/2017Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D- from D on 8/7/2017 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from $1.5 to -$1.15, operating cash flow declined 47.09% from -$57.89M to -$85.15M, and EBIT declined 39.91% from -$39.01M to -$54.58M.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D- from D on 8/7/2017 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from $1.5 to -$1.15, operating cash flow declined 47.09% from -$57.89M to -$85.15M, and EBIT declined 39.91% from -$39.01M to -$54.58M.
D
Sell
6/7/2017Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D from D- on 6/7/2017 due to a major increase in the total return index, growth index and solvency index. Total revenue increased 201.46% from $5.42M to $16.34M, earnings per share increased from -$1.6194 to $1.5, and EBIT increased 54.62% from -$85.96M to -$39.01M.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to D from D- on 6/7/2017 due to a major increase in the total return index, growth index and solvency index. Total revenue increased 201.46% from $5.42M to $16.34M, earnings per share increased from -$1.6194 to $1.5, and EBIT increased 54.62% from -$85.96M to -$39.01M.
D
Sell
3/11/2016Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, solvency index and valuation index.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, solvency index and valuation index.
D
Sell
2/27/2015Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D from C- on 2/27/2015 due to a significant decline in the efficiency index, growth index and solvency index. Total revenue declined 97.45% from $1.06M to $27, debt to equity increased from 0.02 to 0.03, and the quick ratio declined from 10.53 to 5.77.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D from C- on 2/27/2015 due to a significant decline in the efficiency index, growth index and solvency index. Total revenue declined 97.45% from $1.06M to $27, debt to equity increased from 0.02 to 0.03, and the quick ratio declined from 10.53 to 5.77.
C
Hold
11/7/2014Upgraded
Sarepta Therapeutics, Inc. (SRPT) was upgraded to C- from D on 11/7/2014 due to a significant increase in the efficiency index, valuation index and total return index.
Sarepta Therapeutics, Inc. (SRPT) was upgraded to C- from D on 11/7/2014 due to a significant increase in the efficiency index, valuation index and total return index.
D
Sell
3/7/2014Downgrade
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D from D+ on 3/7/2014 due to a decline in the efficiency index, total return index and valuation index. Net income declined 79.01% from -$42.03M to -$8.82M.
Sarepta Therapeutics, Inc. (SRPT) was downgraded to D from D+ on 3/7/2014 due to a decline in the efficiency index, total return index and valuation index. Net income declined 79.01% from -$42.03M to -$8.82M.
NASDAQ
03/06/2025 4:00PM Eastern
Quotes delayed
